Viewing Study NCT06077760


Ignite Creation Date: 2025-12-25 @ 2:17 AM
Ignite Modification Date: 2026-03-15 @ 4:40 AM
Study NCT ID: NCT06077760
Status: RECRUITING
Last Update Posted: 2025-12-18
First Post: 2023-10-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer View
Keywords: